Association of fatty liver index with sudden cardiac arrest in young adults DOI
Joo Hee Jeong, Yun Gi Kim, Kyungdo Han

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 158, P. 155981 - 155981

Published: July 22, 2024

Language: Английский

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease DOI
Niki Katsiki, Genovefa Kolovou, Michal Vráblík

et al.

Current Cardiology Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 13, 2025

Language: Английский

Citations

1
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease DOI
Jacob J. Gries, Jeffrey V. Lazarus, Paul Brennan

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 10(1), P. 82 - 94

Published: Dec. 11, 2024

Language: Английский

Citations

4
MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis DOI Open Access
Alessandro Mantovani, Riccardo Morandin,

Elena Sani

et al.

Liver International, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 25, 2024

Studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and increased risk of developing atrial fibrillation (AF). However, the magnitude whether this varies with severity MASLD remains uncertain.

Language: Английский

Citations

4
Sudden cardiac death associated with fatty liver disease DOI Creative Commons

Jonathan Vo,

Thien Tan Tri Tai Truyen, Audrey Uy‐Evanado

et al.

IJC Heart & Vasculature, Journal Year: 2025, Volume and Issue: 56, P. 101602 - 101602

Published: Jan. 6, 2025

Language: Английский

Citations

0
Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study DOI
Peng Yu, Peng Wang, Fubin Liu

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Abstract Background Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories steatotic (SLD) recently proposed by nomenclature consensus group cancer risk. Methods A total 283 238 participants from the UK Biobank were included. Based on information cardiometabolic factors, alcohol consumption specific aetiology SLD, individuals categorized into four groups: no SLD ( n = 170 885), metabolic dysfunction‐associated (MASLD, 74 510), MASLD intake (MetALD, 23 320) other 6718). Outcomes overall incident 39 352) 21 site‐specific The Cox proportional hazards model used estimate relationships factors in Population attributable risk (PAR) estimated. Results most prevalent general population. All elevated cancer, digestive system cancers (except gastric cancer) breast (HRs 1.079–4.663). Additionally, renal endometrial Hodgkin lymphoma. Compared MetALD SLDs, has a higher PAR% for majority aforementioned This could largely explained its common abnormalities, dominantly characterized overweight/obesity blood pressure, concomitant hyperglycaemia hyperlipidaemia. Conclusions particularly multiple cancers, providing perspective prevention.

Language: Английский

Citations

0
Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation DOI Creative Commons
Yu Wang, Zheng Chen, Bo Wei

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 21, 2025

Atrial fibrillation (AF) is a common arrhythmia often treated with cryoballoon ablation. The impact of Metabolic-associated fatty liver disease (MASLD), condition newly defined by index ≥ 60, on AF recurrence post-ablation unclear. We analyzed 303 patients undergoing ablation for AF. Cox proportional hazards models were used to assess the relationship between MASLD and recurrence. Paroxysmal atrial was present in 61.1% 63% male. Among patients, 23.4% had MASLD. These exhibited larger left diameter ventricular end-diastolic dimension. During median follow-up 14 months, more frequent (45.1% vs. 20.7%). independently predicted (HR, 2.24 [95% CI 1.35–3.74], P = 0.002), alongside persistent AF, longer duration, diameter. consistently demonstrated significant association an increased risk both paroxysmal 2.38 CI, 1.08–5.23], 0.031) 2.55 1.23–5.26], 0.011). significantly increases after ablation, highlighting importance supporting targeted interventions periprocedural management

Language: Английский

Citations

0
Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study DOI Creative Commons

So Hyun Cho,

Gyuri Kim,

Kyu‐na Lee

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 3, 2025

Language: Английский

Citations

0
Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study DOI

Yehua Tang,

Jianling Fan,

Xingyun Hou

et al.

IJC Heart & Vasculature, Journal Year: 2025, Volume and Issue: 58, P. 101676 - 101676

Published: April 8, 2025

Language: Английский

Citations

0
Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database DOI Creative Commons
Satoru Mitsuboshi,

Shungo Imai,

Hayato Kizaki

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 89(2), P. 106202 - 106202

Published: June 17, 2024

Language: Английский

Citations

3
Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups DOI Creative Commons
Eun Ju Cho, Goh Eun Chung, Jeong‐Ju Yoo

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 12, 2024

Language: Английский

Citations

2